Acuta Capital Erasca Bets Big on Targeted Cancer Therapies
A niche investment move places acuta capital erasca (eras) at the center of Erasca's ambitious quest in targeted canc...
Learn Which Altcoins Pass Fundamental Test by applying a consistent framework that weighs tech, governance, and economics before investing.
23,646 articlesA niche investment move places acuta capital erasca (eras) at the center of Erasca's ambitious quest in targeted canc...
The WHO has declared the latest ebola outbreak a public health emergency of international concern, prompting a wave o...
As BioHarvest gears up for its Q1 2026 earnings, investors seek clarity on revenue momentum, margins, and the path to...
Solana just posted a landmark quarter with over $1 trillion in on-chain activity. This article unpacks what that mile...
In a market of flashing headlines, a few steady names stand out for reliable income. This guide breaks down three blu...
Susquehanna lifts Baidu's price target to $140 while maintaining a Neutral rating, citing AI Cloud strength but ongoi...
Sea Limited blends e-commerce, gaming, and fintech in Southeast Asia. This article explores whether its stock is a li...
Investing in early-stage biotech requires a steady playbook. This article breaks down Lantern Pharma (LTRN) in 2025, ...
Ackman's bold pivot away from Alphabet toward AI bets has investors talking. This guide breaks down what happened, wh...
MRED suspended its listing feeds to Zillow and Trulia, escalating a courtroom battle with Compass. The dispute could ...
A $700,000 taxable account could generate roughly $19,000 in annual income via direct indexing, combining steady divi...
Income-focused investors flock to AGNC for its big dividend, but the real driver of long-term value is its net intere...